B.
32.7%
CD94
NKG2A
CD4
+T cells
CD8
+T cells
NK cells
0.087% 76.5%
A.
0 2 0 4 0 6 0 8 0 1 00 PBMC TIL * * * * PBMC TIL % NKG2A + 0 .0 0 .5 1 .0 2 0 4 0 6 0 8 0 1 00 * * 0 2 0 4 0 6 0 8 0 1 00 PBMC TIL * * *D.
Overall survivalD.
NKG2A
CD8α
CD8β
CD56
NKp44
NKp46
CD16
CD161
CD45RA CD45RO KLRG1
CCR7
CD127
CD27
CD28
CD103 HLA-DR
CD38
CD25
PD-1
CD7
CD122
tSNE1 tSNE2 high low N K G 2A C D 5 6 C D 2 5 N K p 4 4 C D 10 3 C D 1 2 2 C D 7 H L A -D R C D 1 6 1 T C R γ δ c -K IT C D 1 6 P D -1 C D 8 β C D 3 8 C D 8 α C D 1 2 7 C R T H 2 C D 3 N K p 4 6 C C R 6 C D 4 5 R O C D 4 5 C D 4 5 R A C D 2 8 C D 2 7 C C R 7 K LR G 1 -1 0 1Expression ratio of NKG2A
A.
0 8 24 29 36
TC-1 tumor intratumoural analysis
peptide vaccination days: NKG2A relative counts
B.
72.3 % 73.7 %NK cells
0.41 % 2.02 %CD4 T cells
13.7 % 41.4 %CD8 T cells
% NKG2A + 0 2 0 4 0 6 0 8 0 1 00 * * ** * * *C.
untreated (d24)vaccinated (d24)vaccinated (d29)vaccinated (d36)untreated (d24)vaccinated (d24)vaccinated (d29)vaccinated (d36) untreated (d24)vaccinated (d24)vaccinated (d29)vaccinated (d36)
D.
0 2 0 4 0 6 0
0
1000 untreated
vaccinated
Days after tumor challenge
C.
F.
Untreated Vaccinated + isotype Vaccinated + α-NKG2A α-NKG2A % survivalDays after tumor challenge
** 0 2 0 4 0 6 0 0 5 0 1 00 % survival
Days after tumor challenge
A.
B16
TC-1
0 2 0 4 0 6 0 8 0 0 5 0 1 00 ** % survival Untreated Vaccinated + isotype Vaccinated + α-NKG2ATC-1, Qa-1
b-/-host
Days after tumor challenge
RMA
D.
0 2 0 4 0 6 0 0 5 0 1 00 untreated vaccinated untreatedQa-1
b -vaccinated * % survivalDays after tumor challenge
WT
0 2 0 4 0 6 0 0 5 0 1 00 untreated adjuvant alone vaccinated untreated adjuvant alone vaccinatedQa-1
b-Days after tumor challenge
% survival
B16
*WT
F.
TC-1
0 2 0 4 0 6 0 0 1 ,00 0 untreated vaccinatedQa-1
b-Days after tumor challenge
A.
0 1 ,00 0WT
tumor size (mm 3)Days after tumor challenge
0 2 0 4 0 6 0 0/16 0/16 0/260/17 0 1 ,00 0 WT Qa-1 b -WT Qa-1 b -tumor size (mm 3) *
Day 18
0 1 00 2 00 3 00 WT Qa-1 b -* -*Day 28
untreated vaccinatedB.
C.
0 2 0 4 0 6 0 0 200 tumor size (mm 3)WT
3/20 4/20Days after tumor challenge 0 2 0 4 0 6 0
0 200
untreated vaccinated
Days after tumor challenge
Qa-1
b -4/20 8/20 0 2 0 4 0 6 0 0 2 00 untreated adjuvant alone vaccinated 0/8 0/6 3/6Qa-1
b -tumor size (mm 3)Days after tumor challenge
E.
0 2 0 4 0 6 0 0 200 0/8 0/8 0/7WT
tumor size (mm 3)0 0 1 00
B.
0 2 0 4 0 6 0 0 1 00 vaccinated vaccinated, NK-depleted control vaccinatedQa-1
b -% survivalDays after tumor challenge
ns 0 2 0 4 0 6 0 0 200 vaccinated vaccinated NK depleted control vaccinated
WT
0/10 0/10 4/20 tumor size (mm 3) 0 2 0 4 0 6 0 0 200 vaccinated vaccinated NK depleted control vaccinatedQa-1
b -1/10 3/10 8/20 tumor size (mm 3) 2 0 4 0 6 0 vaccinated vaccinated NK depleted control vaccinatedWT
% survival nsA.
C.
0 5 1 0 1 5 % IFN-γ / CD8WT
ns peptide - + - + - + vaccinated vaccinatedNK depletedvaccinatedcontrol
0 5 1 0 1 5 peptide - + - + - + % IFN-γ / CD8 vaccinated vaccinated
NK depletedvaccinatedcontrol
Qa-1
b-ns